OCF001 Gel for Vaginal Yeast Infection

(BLOSSOM Trial)

JS
Overseen ByJames Smith
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of OCF001 Intravaginal Gel in Women with Acute Vulvovaginal Candidiasis

Who Is on the Research Team?

CM

Christina Muzny, MD

Principal Investigator

UAB Sexual Health Research Clinic

Are You a Good Fit for This Trial?

Inclusion Criteria

I have vulvovaginal itching, burning, or irritation.
I am a woman between 18 and 65 years old.
I have been diagnosed with a yeast infection confirmed by a lab test.
See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive 5 g of OCF001 or placebo vaginal gel once daily for 7 days

1 week
Daily administration

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks
Visits on Days 4, 8, and 25

What Are the Treatments Tested in This Trial?

Interventions

  • OCF001 Intravaginal Gel

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Placebo Group

Group I: OccidiofunginExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Sano Chemicals Inc

Lead Sponsor